Hikma Pharmaceuticals (LON:HIK) Hits New 1-Year High – Here’s What Happened

Shares of Hikma Pharmaceuticals PLC (LON:HIK) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as GBX 2,296 ($28.70) and last traded at GBX 2,294 ($28.68), with a volume of 311692 shares changing hands. The stock had previously closed at GBX 2,282 ($28.53).

Analyst Upgrades and Downgrades

Separately, Berenberg Bank upped their target price on shares of Hikma Pharmaceuticals from GBX 2,400 ($30.00) to GBX 2,560 ($32.00) and gave the company a “buy” rating in a report on Wednesday, January 29th.

Hikma Pharmaceuticals Stock Up 0.5 %

The company has a market capitalization of £5.09 billion, a PE ratio of 3,526.77, a PEG ratio of 2.38 and a beta of 0.41. The company has a debt-to-equity ratio of 55.48, a quick ratio of 1.27 and a current ratio of 1.66. The stock’s 50 day moving average is GBX 2,031.59 and its 200 day moving average is GBX 1,960.13.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.